Wide Ranks

IMNM

Immunome, Inc.

13.47

Top Statistics
Market Cap 840 M Forward PE -5.51 Revenue Growth -18.40 %
Current Ratio 6.17 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -5.44 Enterprise / Revenue 59.30 Price To Sales Trailing12 Months 83.00
Profitability
Profit Margins 0.00 % Operating Margins -1505.70 %
Balance Sheet
Total Cash 240 M Total Cash Per Share 3.85 Total Debt
Total Debt To Equity Current Ratio 6.17 Book Value Per Share 4.97
All Measures
Short Ratio 1599.00 % Message Board Id finmb_108518404 Shares Short Prior Month 10 M
Return On Equity -2.76 City Bothell Uuid c2147e86-3bc9-3a00-bf6a-53fc4499717d
Previous Close 11.53 First Trade Date Epoch Utc 1 B Book Value 4.97
Volume 1 M Price To Book 2.71 Fifty Two Week Low 6.93
Total Cash Per Share 3.85 Total Revenue 10 M Shares Short Previous Month Date 1 B
Target Median Price 31.50 Max Age 86400 Recommendation Mean 1.29
Sand P52 Week Change 0.3133 Operating Margins -1505.70 % Target Mean Price 30.00
Net Income To Common -305348000 Short Percent Of Float 0.1805 Implied Shares Outstanding 62 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 240 M Next Fiscal Year End 1 B
Revenue Per Share 0.1890 Held Percent Insiders 0.1699 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 11.53
Target Low Price 21.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 12.37
Open 11.68 Free Cashflow -104477128 State WA
Dividend Yield 0.00 % Return On Assets -0.3989 Time Zone Short Name EST
Trailing Eps -7.94 Day Low 11.62 Address1 18702 N. Creek Parkway
Shares Outstanding 62 M Price Hint 2 Target High Price 38.00
Website https://immunome.com 52 Week Change 0.8056 Average Volume 767590
Forward Eps -2.90 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 607.50 % Is_sp_500 False Regular Market Day High 13.53
Profit Margins 0.00 % Fifty Two Week High 30.96 Day High 13.53
Shares Short 10 M Regular Market Open 11.68 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 59.30 Revenue Growth -18.40 %
Shares Percent Shares Out 0.1709 Operating Cashflow -86193000 Currency USD
Time Zone Full Name America/New_York Market Cap 840 M Is_nasdaq_100 False
Zip 98011 Quote Type EQUITY Industry Biotechnology
Long Name Immunome, Inc. Regular Market Day Low 11.62 Held Percent Institutions 0.8347
Current Price 13.47 Address2 Suite 100 Enterprise To Ebitda -5.44
Financial Currency USD Current Ratio 6.17 Gross Margins 6.03 %
Industry Disp Biotechnology Number Of Analyst Opinions 6 Country United States
Float Shares 44 M Two Hundred Day Average 15.74 Enterprise Value 600 M
Price To Sales Trailing12 Months 83.00 Forward PE -5.51 Regular Market Volume 1 M
Ebitda -110441000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Immunome, Inc., a biotechnology company, develops targeted cancer therapies.

The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.